Registry projects: Anaemia

Service Evaluation and the VEST
study
Fraser Cummings
Clinical lead UK IBD Registry

© IBD Registry. All rights reserved

ibdregistry.org.uk

Anaemia Service Evaluation
Joint Working Agreement model- Pharmacosmos
Objectives
1. Observe proportion of 100 IBD patients who have
IDA of ID
2. What treatment they receive
3. Quantify iron dosing and iron deficit
4. Assess Patient PROM in relationship to treatment
5. Potentially inform future audit

© IBD Registry. All rights reserved

ibdregistry.org.uk

Anaemia Service Evaluation
• Management of iron deficiency in IBD
patients in 5 hospitals in the UK
• 10 consecutive UC and 10 CD outpatients
• 1 year follow up of patient

© IBD Registry. All rights reserved

ibdregistry.org.uk

Anaemia Service Evaluation




Patient phenotype
Medication history
IBD Control PROM
Disease activity score
Routine blood test results at 2 time points
1 year apart

© IBD Registry. All rights reserved

ibdregistry.org.uk

VEST: The UKVedolizumab real life experience
studyin inflammatorybowel disease
Dr Peter Irving1 Dr Keith Bodger and Dr Fraser Cummings2
Summary
Thisproject aimsto capture dataon the real life experience of the introduction
of vedolizumab to routine care of IBDpatients in the UKusingthe national IBD
registry.

© IBD Registry. All rights reserved

ibdregistry.org.uk

How to deliver it?
• Modified UK IBD Registry Web Tool
• Data entry costs (Band 6 nurse 6 hours
per patient)
• Registry IG structure
• Patients: study specific consent
• NIHR Portfolio

© IBD Registry. All rights reserved

ibdregistry.org.uk

Primary Outcomes
The primary outcome will be steroid-free remission at one year as
defined by an HBI at week 56 of ≤4 or a UCDAI ≤2.
Secondary Outcomes
Secondary outcomes will include but not be limited to:
•Remission and response rates at Week 6, 14, Week 30 and Week 54
•Durable remission / response ie at week 14, 30 and 54
•Effect of vedolizumab on disease activity as measured by the PRO2,
IBD control PROM, Physician’s Global Assessment and biomarkers of
disease activity
•Health care usage at 1 year using HES data (to be confirmed)
•Tolerance and safety of vedolizumab at 1 year
•Description of the demographics, disease phenotype, disease and
treatment history and concomitant medication use of patients receiving
vedolizumab
© IBD Registry. All rights reserved

ibdregistry.org.uk

• SB2/Flixabi (Samsung/Biogen)
• Submitted as part of RMP to EMA

© IBD Registry. All rights reserved

ibdregistry.org.uk

Conclusions
• Flexible platform for delivering investigator
initiated multi centre research
• Piloting of IBD audit topics
• Joint working models
• Pharmacovigilance

© IBD Registry. All rights reserved

ibdregistry.org.uk